Denali Therapeutics Inc
Change company Symbol lookup
Select an option...
DNLI Denali Therapeutics Inc
GAB Gabelli Equity Trust
WTR Aqua America Inc
BAC Bank of America Corp
BBL BHP Group PLC
NOK Nokia Oyj
LMAT LeMaitre Vascular Inc
CXW CoreCivic Inc
SITE SiteOne Landscape Supply Inc
NVDA NVIDIA Corp
Go

Health Care : Biotechnology | Company profile

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

Closing Price
$20.97
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
257,052
0

Canopy Growth to Announce Third Quarter Fiscal 2019 Financial Results

2:00 pm ET January 15, 2019 (PR Newswire) Print

Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) will release its financial results for the third quarter fiscal 2019 ended December 31, 2018 after financial markets close on February 14, 2019.

https://mma.prnewswire.com/media/808660/Canopy_Growth_Corporation_Canopy_Growth_to_Announce_Third_Quarte.jpg

Following the release of its third quarter 2019 financial results, Canopy Growth will host a conference call and audio webcast with Bruce Linton, Chairman & Co-CEO and Tim Saunders, EVP & CFO at 8:30 AM Eastern Time on February 15, 2019.

Webcast Information A live audio webcast will be available at: https://event.on24.com/wcc/r/1913031/9F3A6AC5FFF944BE38A01DF2D130074D

Calling Information Toll Free Dial-In Number: 1-888-231-8191 International Dial-In Number: (647) 427-7450 Conference ID: 4179499

Replay Information A replay of the call will be accessible by telephone until 11:59 PM ET on May 14, 2019. Toll Free Dial-in Number: 1-855-859-2056 Replay Password: 4179499

About Canopy Growth Corporation Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth offers medically approved vaporizers through the Company's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over 15 countries across five continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its wholly owned subsidiary, Canopy Health Innovations ("Canopy Health"), has devoted millions of dollars toward cutting edge, commercializable research and IP development. Canopy Growth works with the Beckley Foundation and has launched Beckley Canopy Therapeutics to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. Canopy Growth acquired assets of leading hemp research company, ebbu, Inc. ("ebbu"). Intellectual Property ("IP") and R&D advancements achieved by ebbu's team apply directly to Canopy Growth's hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, Battelle, the world's largest nonprofit research and development organization, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. The Company operates Tweed retail stores in Newfoundland and Manitoba and has entered into supply agreements with every Canadian province and territory. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to international operations in the LATAM region. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company's ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company's annual information form dated June 27, 2018 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

https://c212.net/c/img/favicon.png?sn=MO24435&sd=2019-01-15

View original content to download multimedia:http://www.prnewswire.com/news-releases/canopy-growth-to-announce-third-quarter-fiscal-2019-financial-results-300778721.html

SOURCE Canopy Growth Corporation

https://rt.prnewswire.com/rt.gif?NewsItemId=MO24435&Transmission_Id=201901151400PR_NEWS_USPR_____MO24435&DateId=20190115

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.